Showing results (2161-2170 of 8,257) with videos related to

Sort By:
Pageof 826
Haematologica|August 5, 2017
Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talkMartijn Ha van Attekum, Eric Eldering, Arnon P Kater
Haematologica|August 5, 2017
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approachIris de Weerdt, Suzanne M Koopmans, Arnon P Kater, et al.
Haematologica|August 5, 2017
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphomaAlessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, et al.
Haematologica|September 2, 2017
HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosisRui Huang, Yoshihiro Hayashi, Xiaomei Yan, et al.
Haematologica|September 2, 2017
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitorTiziana Vaisitti, Federica Gaudino, Samedy Ouk, et al.
Haematologica|September 2, 2017
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trialYasuhiro Oki, Kevin R Kelly, Ian Flinn, et al.
Haematologica|July 29, 2017
Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemiaBenjamin Kobitzsch, Nicola Gökbuget, Stefan Schwartz, et al.
Haematologica|July 29, 2017
Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphomaLaurent Jallades, Lucile Baseggio, Pierre Sujobert, et al.
Haematologica|July 9, 2016
A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patientsHendrika Hazendonk, Karin Fijnvandraat, Janske Lock, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Pageof 826